Emicizumab
Emicizumab Basic information
- Product Name:
- Emicizumab
- Synonyms:
-
- Emicizumab
- Research Grade Emicizumab (DHB87901)
- Emicizumab (anti-Factor IX)
- ACE 910|||RO 5534262
- Research Grade Emicizumab
- CAS:
- 1610943-06-0
- MW:
- 0
- Mol File:
- Mol File
More
Less
Emicizumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Emicizumab Usage And Synthesis
Uses
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research[1].
in vivo
Emicizumab (1.5-10 mg/kg, IV, 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia A bleeding model, with an FVIII equivalence of 9 U/dL[1].
Emicizumab (3 mg/kg, IV) provides additive hemostatic activity when given in combination with low-dose FVIII (10 U/dL)[1].
| Animal Model: | FVIII-deficient mice[1] |
| Dosage: | 1.5-10 mg/kg |
| Administration: | IV, 24 hours before tail-clip bleeding was performed |
| Result: | Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice. |
References
[1] Ferrière S, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020 Aug 6;136(6):740-748. DOI:10.1182/blood.2019004334
EmicizumabSupplier
Wuhan Sunrise Technology Development Co., Ltd.
- Tel
- 27-027-83314682 13554138826
- whsrtech@vip.163.com
Nanjing Sunlida Biological Technology Co., Ltd.
- Tel
- 025-57798810
- sales@sunlidabio.com
Shanghai EFE Biological Technology Co., Ltd.
- Tel
- 021-65675885 18964387627
- info@efebio.com
Shanghai YuanYe Biotechnology Co., Ltd.
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
Hefei Hirisun Pharmatech Co., Ltd.
- Tel
- +86-0551-62678551 +86-15056975894
- sales@hirisunpharm.com